Connect with us

Technology

Ariceum Therapeutics Presents Outstanding Data on its First-in-Class Radiopharmaceutical Drug 225Ac-Satoreotide at the European Association of Nuclear Medicine 2024

Published

on

225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical developmentSatoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clinical anti-tumour efficacy, irrespective of radionuclide used100% survival with a single dose of 30 kBq 225Ac-satoreotide but not with 225Ac-DOTA-TATE

BERLIN, Oct. 22, 2024 /PRNewswire/ — Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it presented data on its proprietary radiolabelled peptide SS0110 (satoreotide), a first-in-class antagonist of the somatostatin receptor 2 (SSTR2), at this year’s European Association of Nuclear Medicine (EANM) Annual Conference, held in Hamburg, Germany from 19-23 October 2024.

The Top-Rated Oral Presentation (TROP) entitled ‘225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts’, details the anti-tumour efficacy of different radiolabelled satoreotide antagonists (225Ac, 161Tb, 177Lu-labelled SSO110) versus respective DOTA-TATE agonists (225Ac- and 161Tb-labelled DOTA-TATE) in mice engrafted with SSTR2 positive xenografts of small cell lung cancer (SCLC) and pancreatic cancer using clinically relevant associated dose ranges.  

Results demonstrate that 225Ac-satoreotide shows the strongest anti-tumoural effect in vivo at a low single dose when evaluating satoreotide and DOTA-TATE radiolabelled with different radionuclides. Irrespective of the radionuclides used, satoreotide demonstrated a higher pre-clinical anti-tumour efficacy when compared to DOTA-TATE which was less potent and required increased dose levels. Satoreotide was well tolerated across all dose levels and with all used radionuclides. These comparisons between satoreotide and DOTA-TATE will facilitate and guide further clinical development of satoreotide across multiple indications expressing SSTR2, such as SCLC, pancreatic cancers and Merkel Cell Carcinoma (MCC).

Previous comparisons between satoreotide and DOTA-TATE demonstrated that antagonist, 225Ac-satoreotide, is multiple times more potent than SSTR2 agonist, 225Ac-DOTA-TATE, signifying a durable complete response in standard murine xenograft models of SCLC in animal models, versus tumour growth delay.

Ariceum had previously shown at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 that 212Pb was not seen to be more potent than Lutetium or Terbium but caused more side effects and hence was not further pursued.

Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: “These results provide strong evidence for satoreotide and its potential to clinically outperform SSTR2 targeting agonists, by demonstrating significantly better efficacy in tumour growth control, up to complete tumour eradication depending on isotope used. In addition, when a single dose of 30 kBq 225Ac-satoreotide was administered, we observed high frequency of complete durable responses and 100% survival which strongly supports further clinical development for the treatment of SCLC, MCC and other cancers.”

Details of the oral presentation are as follow:

Title: 225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts

Presenting Author: Prachi Desai, Scientist at Ariceum Therapeutics

Session Number: 1204
Session Title: M2M Track – TROP Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: From Radionuclide to Clinical Translation

Oral Presentation Date & Time: Tuesday 22 October 2024, 09:00 AM09:10 AM CEST

Abstract Authors: Prachi Desai, Manuel Sturzbecher
–  Hoehne,
Dennis Mewis, Manfred Ruediger & Anika Jaekel  of Ariceum Therapeutics

Abstracts are available in the September edition of Springer’s European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) abstract book here and on the Ariceum website here.

About Ariceum Therapeutics

Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer.

Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“Satoreotide”), is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), or Merkel Cell Carcinoma (MCC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023.

Ariceum Therapeutics, launched in 2021, acquired all rights to Satoreotide from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, United Kingdom and United States of America and with activities currently across the globe.

Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For further information, please visit www.ariceum-therapeutics.com.

About European Association of Nuclear Medicine (EANM)

The European Association of Nuclear Medicine (EANM) is a non-profit organization that promotes nuclear medicine and aims to improve public health. The EANM’s mission is to advance nuclear medicine through personalized healthcare, innovation in diagnosis and treatment, and raising awareness of nuclear medicine

View original content:https://www.prnewswire.co.uk/news-releases/ariceum-therapeutics-presents-outstanding-data-on-its-first-in-class-radiopharmaceutical-drug-225ac-satoreotide-at-the-european-association-of-nuclear-medicine-2024-302282011.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Herbalife India recognised as ‘Top Supply Chain Performer’ at ISCM E-Comm Nexus Awards 2026

Published

on

By

BENGALURU, India, May 11, 2026 /PRNewswire/ — Herbalife India, a premier health and wellness company, community, and platform, has been recognised as a ‘Top Supply Chain Performer’ among Wellness E-Commerce and D2C companies in India at the ISCM E-Comm Nexus Awards 2026, organised by ISCM (Institute of Supply Chain Management) Forums.

ISCM Forums, an independent industry body, conducted an extensive evaluation of more than 1,000 organisations across 29 sectors to identify leading supply chains within India’s Wellness E-Commerce and D2C ecosystem.

The recognition was presented at an industry event held in Mumbai. The award was received on behalf of Herbalife India by Makrand Raorane from the company’s Distribution Team.

Commenting on the recognition, Ajay Khanna, Managing Director, Herbalife India, said, “In the health and wellness category, a strong and agile supply chain plays an important role in ensuring product availability, quality, and a seamless consumer experience. At Herbalife India, we continue to strengthen our supply chain capabilities through operational excellence, efficient distribution networks, and a strong focus on reliability and responsiveness. This recognition reflects our commitment to building a resilient and consumer-centric supply chain ecosystem that supports our long-term growth journey in India.”

Herbalife India’s supply chain operations are focused on enabling efficient product movement, timely deliveries, and consistent service standards across its distribution ecosystem. The company continues to invest in strengthening operational processes and distribution capabilities to support evolving consumer demand in the growing wellness and D2C segment.

This recognition further reinforces Herbalife India’s continued focus on operational excellence, efficiency, and customer-centricity within a rapidly evolving wellness marketplace.

About Herbalife International India Private Ltd.

Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people’s lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed food products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life. For more information, visit https://www.herbalife.com/en-in

Photo: https://mma.prnewswire.com/media/2976688/Herbalife_2026_Award.jpg
Logo: https://mma.prnewswire.com/media/2238437/5962786/Herbalife_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/herbalife-india-recognised-as-top-supply-chain-performer-at-iscm-e-comm-nexus-awards-2026-302768084.html

Continue Reading

Technology

Hello Group to Report First Quarter 2026 Results on June 2, 2026

Published

on

By

BEIJING, May 11, 2026 /PRNewswire/ — Hello Group Inc. (NASDAQ: MOMO) (the “Company”), a leading player in Asia’s online social networking space, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2026 before U.S. markets open on Tuesday, June 2, 2026.

Hello Group’s management will host an earnings conference call on Tuesday, June 2, 2026, at 7:00 a.m. U.S. Eastern Time (7:00 p.m. Beijing / Hong Kong Time on the same day).

Preregistration Information

Participants can register for the conference call by navigating to https://s1.c-conf.com/diamondpass/10054808-suvwn2.html. Upon registration, each participant will receive details for the conference call, including dial-in numbers, conference call passcode and a unique access PIN. Please dial in 10 minutes before the call is scheduled to begin.

A telephone replay of the call will be available after the conclusion of the conference call through June 10, 2026. The dial-in details for the replay are as follows:

U.S. / Canada:

1-855-883-1031

Hong Kong:

800-930-639

Passcode:

10054808

Additionally, a live and archived webcast of the conference call will be available on the Investor Relations section of Hello Group’s website at https://ir.hellogroup.com.

About Hello Group Inc.

We are a leading player in Asia’s online social networking space. Through Momo, Tantan and other properties within our product portfolio, we enable users to discover new relationships, expand their social connections and build meaningful interactions. Momo is a mobile application that connects people and facilitates social interactions based on location, interests and a variety of online recreational activities. Tantan, which we added to our family of applications through acquisition in May 2018, is a leading social and dating application. Tantan is designed to help its users find and establish romantic connections as well as meet interesting people. Since 2019, we have continuously expanded our portfolio through internal incubation and strategic acquisitions, adding apps such as Hertz, Soulchill, and Happn. These products target more niche markets and selective user demographics both domestically and internationally, further strengthening our global presence.

For investor and media inquiries, please contact:

Hello Group Inc.

Investor Relations
Phone: +852-3157-1669
Email: ir@hellogroup.com

Christensen

In China
Ms. Xiaoyan Su
Phone: +86-10-5900-1548
E-mail: Xiaoyan.Su@christensencomms.com 

 

View original content:https://www.prnewswire.com/news-releases/hello-group-to-report-first-quarter-2026-results-on-june-2-2026-302768030.html

SOURCE Hello Group Inc.

Continue Reading

Technology

TrustCloud Introduces Agentic, Data-Driven Third Party Cyber Assessments to Replace Fundamentally Broken Questionnaire-Based Third Party Risk Management (TPRM)

Published

on

By

Company Replaces Low-Confidence, Point-in-Time Workflows so Enterprises can Continuously Analyze Outside-in Security Feeds and Vendor Security Posture Artifacts to Accurately Identify Gaps and Complete Risk Assessments

BOSTON, May 11, 2026 /PRNewswire/ — TrustCloud®, the AI-native Security Assurance Platform for enterprise CISOs, announced a new version of TrustLens®, the company’s Third Party Risk Management (TPRM) solution. The new TrustLens agentic AI capabilities focus on delivering four critical requirements every CISO wants in their TPRM program: speed, accuracy, coverage, and proactive risk mitigation.

In the latest TrustLens deployments, a Global 2000 life sciences customer leveraged the TPRM AI agent within TrustLens to assist their human agents. As a result, they were able to assess more than 5000 suppliers in six months (a 10x improvement). The TrustLens agent enabled deterministic and accurate risk assessments using a unique combination of AI models and rules, expanded assessed vendor coverage from 20% to 92% of its ecosystem, and identified 4x more critical gaps about their vendors compared to the prior process, resulting in proactive remediation by their supplier landscape.

“Our industry has normalized a version of TPRM that is process-driven rather than outcome-driven, where teams are rewarded for following a rigid process to complete assessments instead of reducing risk and leveraging agentic AI to automate process and improve accuracy,” said Jikku Venkat, Head of Product, Customer Assurance and Third-Party Risk, TrustCloud. “We have introduced an AI agent in TrustLens that automates greater than 70% of the assessment work while still giving the risk analyst control over final decisions and approvals. This replaces point-in-time attestations with continuous proof that stands up to scrutiny at any moment.”

For years, organizations have operated under a model that rewards activity over outcomes, where teams send questionnaires, collect self reported answers, and produce reports that create a sense of diligence while leaving the underlying risk largely untouched. TrustCloud now challenges one of the most deeply entrenched and quietly dangerous assumptions in enterprise security: the belief that documenting risk is the same as managing it. With its new version of the TrustLens product, TrustCloud is now making it clear that the legacy TPRM approach is not just inefficient but fundamentally broken in a world where third party ecosystems are the dominant source of cyber exposure.

With TrustLens’ new agentic AI capabilities, customers now have:

The ability to automatically scope every assessment based on its inherent risk tier; the agent makes it possible to move from one-size fits all questionnaires to right-sizing every single assessment

Real-time knowledge of a vendor’s profile, risks and gaps, and analysis of evidence and data to reduce endless back-and-forth time wasted in manually waiting for and analyzing responses

Intelligent risk summaries, citing documentation, inside-out, outside-in data to accurately complete assessments in a deterministic and auditable fashion

Insights and Q&A to understand business impact of risk factors, allowing anyone to ask questions about the risk posture and gaps with a vendor

Up-to-date security posture data to enable proactive monitoring of security drift and continuously track new risks from a previously completed vendor assessment

TrustCloud’s position is unapologetically direct, which is that most third party risk programs today are not designed to prevent incidents or mitigate risks but to show that someone is completing an assessment to check a box. In an environment where the vast majority of enterprises have already experienced third party-driven breaches, that distinction is no longer acceptable.

“As organizations face increasing regulatory pressure, expanding vendor ecosystems, and a growing gap between perceived and actual risk, we need clear signals that the era of checkbox-driven TPRM is over,” said Dan Walsh, CISO, Datavant. “The future of risk assessment and reporting will require us to understand, report, and reduce risk with transparency, automation, and a data-driven approach that operates 24×7 across our entire vendor landscape.”

“With this launch, we are disrupting the TPRM status quo by eliminating a process that is simply frustrating for both the assessor and the third party,” said Tejas Ranade, Co-founder and CPO, TrustCloud. “We are replacing every broken manual workflow created by ineffective TPRM tools of the past with agentic, continuous data driven assessments that defend an organization from supply chain risk and allow CISOs to finally use their TPRM process as a high-confidence predictor of risk.”

TrustLens® TPRM from TrustCloud is available now. Connect with us for a chat or a demo.

About TrustCloud
TrustCloud is the only Security Assurance Platform that provides AI-native GRC transformation for Chief Information Security Officers. Purpose-built for Global 2000 scale, TrustCloud enables organizations to replace point-in-time, sampling-based assessments with continuous, evidence-backed security assurance, reducing internal audit times from 28 days to three, achieving up to 12× ROI by linking compliance to revenue, and saving an average of 63 person-days of manual work per user annually. Learn more at trustcloud.ai.

TrustCloud®, TrustOps®, TrustShare®, TrustRegister®, TrustLens® and TrustHQ® are registered trademarks of TrustCloud Corporation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trustcloud-introduces-agentic-data-driven-third-party-cyber-assessments-to-replace-fundamentally-broken-questionnaire-based-third-party-risk-management-tprm-302761312.html

SOURCE TrustCloud

Continue Reading

Trending